information for payers and referrers

Transcription

1 a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit

2 o u r expertise Since its founding in 1972, our program has performed more than 7,100* transplants for adult patients making us one of the largest and most experienced transplant centers We performed more than 540 transplants in anywhere in the world. In addition, our program: Consistently exceeds expected outcomes established by the Center for International Blood and Marrow Transplant Research (CIBMTR) *Includes transplants since While our transplant center has been operational since 1972, data capture using current standards began in November Currently follows nearly 4,000 patients over the long term Page 2 of 13 Spring 2014 For more information, visit

3 t r a n s p l a n t s performed by donor type Transplants Performed by donor type Transplant Type Historical Program Volume Autologous Allogeneic (Related Donors) Allogeneic (Unrelated Donors) Other (Cord Blood, Mismatched) Total transplants performed 1982 through 2013: 7173 Transplants (Allogeneic) performed by conditioning intensity Conditioning Regimen Intensity Transplants Performed Through 2013 Myeloablative 1978 Non-myeloablative 1596 Total Allogeneic transplants performed, 1982 through Page 3 of 13 Spring 2014 For more information, visit

4 transpl ants performed by disease group Transplants Performed by Disease Group Primary Disease Total Performed 1982 Through 2013 AML 1298 CLL, SLL, PLL 408 CML 413 Hodgkin Disease 473 Multiple Myeloma/Plasma Cell Disorder 1496 Other Malignancy 34 Anemia/Red Cell Disorder 93 Immunodeficiency 2 ALL 371 Other Acute Leukemia 15 MDS 424 MPD 73 Mixed MDS/MPD 16 NHL 2052 Other Disease 5 All Diseases 7173 Page 4 of 13 Spring 2014 For more information, visit

5 transpl ants performed in older adults (55+) As a direct result of major advances in transplantation protocols propelled significantly by insights gleaned from the work of our researchers the number of older adults undergoing transplant continues to grow. Transplants Performed by donor type in Older Adults Transplant Type Autologous Allogeneic Allogeneic (Unrelated Donors) Other (Cord Blood, Mismatched) Total transplants performed 1982 through 2013: 2778 Page 5 of 13 Spring 2014 For more information, visit

6 b r e a d t h and depth of specializat i o n more than 30 credentialed tr anspl ant physicians on staff All are faculty members of Harvard Medical School Includes past and present leaders within such organizations as the American Society for Blood and Marrow Transplantation (ASBMT), Blood and Marrow Trials Clinical Trial Network (BMT-CTN), Center for International Blood and Marrow Transplant Research (CIBMTR), and Cancer and Leukemia Group B (CALGB) c r e d e n t i a l e d t r a n s p l a n t p h y s i c i a n s s p e c i a l i z e d t r a n s p l a n t e x p e r t i s e m u lt i d i s c i p l i n a r y t r a n s p l a n t team expertise that goes beyond tr anspl ant to subspecialty and sub-subspecialty by disease each patient is assigned their own team of tr anspl ant specialists Attending transplant physician Transplant nurse practitioner/physician assistant Post-transplant nurse practitioner/ physician assistant RN transplant coordinator Non-RN transplant coordinator Transplant social worker Unrelated donor search coordinator or related donor collection coordinator Financial counselor Clinical data specialist For patients enrolled in clinical trials: Transplant research nurse and clinical research coordinator Page 6 of 13 Spring 2014 For more information, visit

7 d i s e a s e s and conditions we treat We treat patients who have been diagnosed with the following conditions, including older adults and those with advanced disease: Myeloproliferative disorders and myelodysplastic syndrome Blood cancers Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Chronic lymphocytic leukemia (CLL) Chronic myelogenous leukemia (CML) Hodgkin lymphoma Multiple myeloma Non-Hodgkin lymphoma Waldenström s Macroglobulinemia Myelodysplasia Myelofibrosis Polycythemia Vera Essential Thrombocythemia Bone marrow failure syndromes and rare and congenital blood diseases Aplastic anemia Diamond-Blackfan anemia Other malignant and non-malignant disorders Testicular cancer Dyskeratosis congenita Paroxysmal nocturnal hemoglobinuria (PNH) Shwachman-Diamond syndrome Sickle cell anemia Thalassemia Page 7 of 13 Spring 2014 For more information, visit

8 o u r focus on qua l i t y Team of Quality Assurance, Close collaboration with Commitment to identifying Cost-conscious Quality Control, and community providers and the best therapy for the approach to care Quality Improvement experts practices on financial, care individual patient dedicated to transplant continuation, and quality and cellular therapies issues Robust screening Only proceeding with transplantation when indicated by strong clinical and scientific evidence Ongoing multidisciplinary case review Dedicated specialty consult services including infectious disease, nephrology, and metabolic disorders for transplant patients Medication management Discharging patients as early as deemed advisable One of the nation s most experienced unrelated donor search teams Routinely reviews strategies for finding the best donor for each patient, in the shortest timeframe, at least possible cost Active senior clinical research team investigating and actively publishing on cost reduction and outcomes improvement projects Data collection and reporting Internal and external audits Deviation reporting Adverse event support Preparation of reports for outside agencies and sponsors relative to QA Regulatory support for protocols, Investigative New Drug (IND)/ Device Exemption (IDE) Agreement and contract assurances Safety and infection control Process control Document control Staff education and competency assessments Dedicated support for referrers and payers Online portal for management of all referred patients Secure access to medical records, discharge summaries, and lab reports Notification of inpatient and Emergency Room admissions and discharges Education of regional referring provider practices on caring for patients post-transplant Page 8 of 13 Spring 2014 For more information, visit

9 o u r research initiat i v e s Research program Outcomes data system Quality, safety, and operations research Thriving enterprise in both basic science and translational research Standard patient therapies often include participation in major multicenter clinical trials Breakthroughs and innovations including: Development of novel agents for preventing and managing graft-versus-host disease (GVHD) Vaccination with genetically engineered tumor cells to induce anti-tumor activity and prevent post-transplant relapse Use of counterstimulatory blockade to restore graft-versus-leukemia activity Collaboration with infectious disease specialists to provide access to new antibiotics and newer diagnostic techniques Detection and quantification of minimal residual disease as a method of assessing post-transplantation disease status Historic involvement in development of national reporting metrics and standards and analysis of outcomes data Following all transplant patients throughout their lifetimes and reporting on millions of data points each year Direct data submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) national outcomes database Ongoing metrics and research studies to evaluate cost and outcomes Exploring patient education and self-assessment options for improving outcomes Publications in national and international journals and presentations at major meetings and conferences Focus areas including: Drug interactions in hematopoietic stem cell transplantation (HSCT) Reducing unnecessary testing on admission in autologous stem cell transplant patients Costs of allogeneic HSCT using reduced intensity conditioning regimens Improving novel predictive parameters in apheresis Ongoing quality improvement project to lower the rate of bacterial contamination in HPC-marrow products Page 9 of 13 Spring 2014 For more information, please visit our website at

10 e xc e l l e n c e in cellu l a r ther a p y On-site Connell and O Reilly Families Cell Manipulation Core Facility New England s only Class 10,000 Good Manufacturing Practices (GMP) cell therapy facility at an academic medical center Manufactures cellular products for clinical use, including: Hematopoietic stem cells Tumor vaccines Immunotherapeutic cells Gene therapy products Supports process development for new cell therapy clinical research protocols Provides regulatory support for Investigative New Drug (IND) applications therapy clinical research protocols Processes and cryopreserves patient samples to evaluate outcomes of cell therapy protocols Performs sterility checks and other testing of cellular therapy products Manages a major tissue bank for samples of patients with blood cancers and other related disorders Page 10 of 13 Spring 2014 For more information, visit

11 c o m p r e h e n s i v e offerings Comprehensive services and support for patients and families Pre- and post-transplant collaboration with local physicians and medical centers enabling follow-up care close to patients homes Graft-versus-host disease prevention and management Specialized programs for transplantation Imaging Infectious disease Pathology Radiation oncology Photopheresis oncology Consultation, confirmation of diagnosis, and review of therapeutic options Hematopathologic evaluation and diagnosis Toxicity management Nutrition services Pharmacy services Comprehensive patient education program Focus on post-transplant precautions, medication adherence, and urgent care Expanding to include distributed and blended learning tools Dedicated social work resources Patient and family resource center Emotional and psychosocial support, including private online support community Financial counseling Housing assistance Adult Survivorship Program and other specialized services over the long term, with emphasis on living well beyond cancer Dedicated caregiver guide and support Integrated therapies Performing thorough sequencing on the DNA of abnormal cells from patients with leukemia and related disorders Page 11 of 13 Spring 2014 For more information, visit

12 a c c r e d i tat i o n s and affiliat i o n s Program accreditations Foundation for the Accreditation of Cellular Therapy (FACT) U.S. Food and Drug Administration (FDA) American Association of Blood Banks (AABB) Centers for Medicare & Medicaid Service The Joint Commission Clinical and research affiliations Member of the Center for International Blood and Marrow Transplant Research (CIBMTR) Fully accredited by the National Marrow Donor Program (NMDP) Member of the Cancer and Leukemia Group B (CALGB) Charter member of the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) of the National Institutes of Health Both Dana-Farber Cancer Institute and Brigham and Women s Hospital are founding members of Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute Page 12 of 13 Spring 2014 For more information, visit

13 k e y conta c t s Mailing Address: Dana-Farber/Brigham and Women s Cancer Center Adult Stem Cell Transplantation Program 450 Brookline Avenue, Dana 2 Boston, MA Patient referrals and consultation/second opinion requests: 877-DFCI-BWH ( ) Managed care inquiries: Diane P. Lanahan, MBA, RN, Director of Managed Care Contracting diane_lanahan@dfci.harvard.edu Financial counseling and support requests: Page 13 of 13 Spring 2014 For more information, visit